Target | Research object | Effect on tumor | References |
---|---|---|---|
STC2 | Gastric cancer | Inhibit the proliferation and invasion | [56] |
CENPF | Gastric cancer | Inhibit the proliferation, migration, and invasion | [57] |
G6PD | Gastric cancer | Inhibit the Warburg effect Inhibit cell proliferation and promote cell apoptosis | [30] |
YWHAZ | Colorectal cancer | Inhibit the proliferation and invasion | [65] |
IGF1 | Colorectal cancer | Inhibit the proliferation and promote their apoptosis | [66] |
NAMPT | Colorectal cancer | Form a negative feedback pathway | [70] |
CENPF | Lung adenocarcinoma | Inhibit proliferation and migration | [73] |
FAM83A | Lung cancer | Inhibit the proliferation, invasion, and migration | [74] |
CELSR3 | Lung adenocarcinoma | Inhibit the proliferation, migration, and invasion | [75] |
/ | Non-small cell lung cancer | Inhibit the proliferation | [29] |
PAICS | Non-small cell lung cancer | Involved in the glycolysis and nucleotide metabolism | [76] |
CCL2 | Bladder cancer | Inhibit cell proliferation, colony formation, migration, and invasion, promote mitosis to stagnate in the G0/G1 phase, and increase the ratio of apoptosis | [83] |
C1GALT1 | Bladder cancer | Inhibit the proliferation and migration | [38] |
GLS | Bladder cancer | Inhibit the proliferation, migration, and invasion | [88] |
BDNF/TrkB | Bladder cancer | Inhibit the proliferation, migration, invasion | [94] |
SOX9 | Hepatocellular carcinoma | Inhibit the proliferation of HCC cells and promote their apoptosis | [99] |
ORC6 | Hepatocellular carcinoma | Inhibit HCC cell proliferation, migration, and invasion, and induce cell cycle arrest and apoptosis | [103] |
/ | Hepatocellular carcinoma | Inhibit angiogenesis | [108] |
IGF1 | Hepatocellular carcinoma | Inhibit the proliferation of HCC cells and promote apoptosis, and more HCC cells stay in G0/G1 phase | [25] |
E2F5 and PFTK1 | Prostate cancer | Inhibit the proliferation and colony forming and make more cells stay in the G0/1 phase | [111] |
CORO1C | Prostate cancer | Inhibit the migration, invasion, and EMT progression | [26] |
LASP1 | Prostate cancer | Inhibit the proliferation and migration and bone metastasis (BM) of Gleason 3 + 4 PCa | [114] |
TAGLN2 | Esophageal cancer | Inhibit the proliferation, colony formation, invasion and promote apoptosis | [117] |
PIK3CA/AKT pathway | Esophageal cancer | Inhibit the proliferation and promote apoptosis | [31] |
CORO1C/TPM3 | Esophageal cancer | Inhibit the migration and invasion | [27] |
DKK1 | Oral squamous cell carcinoma | Inhibit the proliferation, migration, and invasion, block the transition from the G0/G1 phase to the S phase and induce cell apoptosis | [120] |
Fibronectin 1 | Renal cell carcinoma | Inhibit the EMT process and weaken the ability of migration and invasion | [133] |
TNKS2/Wnt/ β-catenin signaling pathway | Ovarian cancer | Inhibit the proliferation, induce cell cycle arrest in the G1/S phase, and promote cell apoptosis | [121] |
c-Met | Ovarian cancer | Block cell cycle progression and inhibit proliferation, migration, and invasion of OA cells | [122] |
Bcl-2 | Breast cancer | Inhibit proliferation, migration, invasion and promote cell apoptosis | [127] |
K-Ras and lncRNA MALAT1 | Breast cancer | Inhibited cell proliferation and motility and promoted apoptosis | [128] |
MEK/ERK | Breast cancer | Inhibit proliferation, migration, invasion | [129] |
BVI-1 | Breast cancer | Inhibit proliferation and EMT-related genes in BCSCs and promote apoptosis | [130] |
MINOS1, GPD2, LRPPRC | Breast cancer | Trigger mitochondrial damage and promote mitochondrial autophagy in BCSCs | [131] |
CDK14 | Osteosarcoma | Inhibit cell proliferation and cell cycle progression while promoting apoptosis | [137] |
Fibronectin 1 | Glioblastoma | inhibit the proliferation and migration of cells | [147] |
YY1 | Medulloblastoma | Promote malignant phenotypes | [148] |
G6PD | Pituitary tumors | Inhibit NADPH production and glycolytic processes; Inhibit proliferation and promote apoptosis | [149] |
VASP/Rap1 axis | Breast cancer | Inhibit the malignant phenotype and chemotherapy resistance of BC cells | [28] |